$5.95
7.40% yesterday
Nasdaq, Nov 15, 09:50 pm CET
ISIN
US23285D1090
Symbol
CTKB

Cytek BioSciences Inc Target price 2024 - Analyst rating & recommendation

Cytek BioSciences Inc Classifications & Recommendation:

Buy
67%
Hold
33%

Cytek BioSciences Inc Price Target

Target Price $8.40
Price $5.95
Potential
Number of Estimates 5
5 Analysts have issued a price target Cytek BioSciences Inc 2025 . The average Cytek BioSciences Inc target price is $8.40. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 4 Analysts recommend Cytek BioSciences Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Cytek BioSciences Inc stock has an average upside potential 2025 of . Most analysts recommend the Cytek BioSciences Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 193.02 204.95
17.67% 6.18%
EBITDA Margin -8.87% 11.35%
423.32% 227.97%
Net Margin -6.05% -3.80%
482.44% 37.20%

6 Analysts have issued a sales forecast Cytek BioSciences Inc 2024 . The average Cytek BioSciences Inc sales estimate is

$205m
Unlock
. This is
1.86% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$206m 2.60%
Unlock
, the lowest is
$203m 0.93%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $193m 17.67%
2024
$205m 6.18%
Unlock
2025
$234m 13.97%
Unlock
2026
$262m 12.37%
Unlock
2027
$289m 9.99%
Unlock
2028
$317m 9.80%
Unlock

4 Analysts have issued an Cytek BioSciences Inc EBITDA forecast 2024. The average Cytek BioSciences Inc EBITDA estimate is

$23.3m
Unlock
. This is
272.68% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$26.2m 294.54%
Unlock
, the lowest is
$20.9m 255.28%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-17.1m 480.44%
2024
$23.3m 235.87%
Unlock
2025
$38.3m 64.74%
Unlock
2026
$49.1m 28.02%
Unlock
2027
$61.3m 24.96%
Unlock
2028
$74.2m 21.04%
Unlock

EBITDA Margin

2023 -8.87% 423.32%
2024
11.35% 227.97%
Unlock
2025
16.40% 44.49%
Unlock
2026
18.69% 13.96%
Unlock
2027
21.23% 13.59%
Unlock
2028
23.41% 10.27%
Unlock

3 Cytek BioSciences Inc Analysts have issued a net profit forecast 2024. The average Cytek BioSciences Inc net profit estimate is

$-7.8m
Unlock
. This is
24.96% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-6.5m 37.49%
Unlock
, the lowest is
$-10.4m 0.02%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-11.7m 550.00%
2024
$-7.8m 33.30%
Unlock
2025
$4.3m 155.58%
Unlock
2026
$3.9m 10.16%
Unlock

Net Margin

2023 -6.05% 482.44%
2024
-3.80% 37.20%
Unlock
2025
1.85% 148.68%
Unlock
2026
1.48% 20.00%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.09 -0.06
550.00% 33.33%
P/E negative
EV/Sales 2.55

3 Analysts have issued a Cytek BioSciences Inc forecast for earnings per share. The average Cytek BioSciences Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.06
Unlock
. This is
25.00% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.05 37.50%
Unlock
, the lowest is
$-0.08 0.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.09 550.00%
2024
$-0.06 33.33%
Unlock
2025
$0.03 150.00%
Unlock
2026
$0.03 0.00%
Unlock

P/E ratio

Current -76.97 63.21%
2024
-99.17 28.84%
Unlock
2025
178.50 279.99%
Unlock
2026
198.33 11.11%
Unlock

Based on analysts' sales estimates for 2024, the Cytek BioSciences Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.60 19.82%
2024
2.55 1.91%
Unlock
2025
2.24 12.26%
Unlock
2026
1.99 11.01%
Unlock
2027
1.81 9.08%
Unlock
2028
1.65 8.93%
Unlock

P/S ratio

Current 3.81 4.39%
2024
3.74 1.82%
Unlock
2025
3.28 12.26%
Unlock
2026
2.92 11.01%
Unlock
2027
2.65 9.08%
Unlock
2028
2.42 8.93%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today